GURUFOCUS.COM » STOCK LIST » USA » NAS » Eiger BioPharmaceuticals Inc (NAS:EIGR) » Definitions » Profitability Rank
Switch to:

Eiger BioPharmaceuticals Profitability Rank

: 1 (As of Jun. 2022)
View and export this data going back to 2014. Start your Free Trial

Eiger BioPharmaceuticals has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Eiger BioPharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 was -490.83%. As of today, Eiger BioPharmaceuticals's Piotroski F-Score is 3.


Competitive Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Eiger BioPharmaceuticals Profitability Rank Distribution

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Profitability Rank falls into.



Eiger BioPharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Eiger BioPharmaceuticals has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Eiger BioPharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-20.08 / 4.091
=-490.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Eiger BioPharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Eiger BioPharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Eiger BioPharmaceuticals Business Description

Eiger BioPharmaceuticals logo
Traded in Other Exchanges
Address
2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Executives
Apelian David director C/O ACHILLION PHARMACEUTICALS, INC 300 GEORGE STREET NEW HAVEN CT 06511
Atkisson Erik officer: GC & Chief Compliance Officer C/O EIGER BIOPHARMACEUTICALS, INC. 2155 PARK BLVD. PALO ALTO CA 94306
Sablich Kim director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mayer Eldon C. Iii officer: Ex VP & Chief Commerc. Officer RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO CA 94080
Ryali Sriram officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC. 2155 PARK BLVD. PALO ALTO CA 94306
Cory David A director, officer: President and CEO 350 CAMBRIDGE AVENUE, SUITE 350 PALO ALTO CA 94306
Loh Evan director 75 KNEELAND STREET BOSTON MA 02111
Murray Christine director C/O ACHAOGEN, INC. 7000 SHORELINE COURT, SUITE 371 SOUTH SAN FRANCISCO CA 94080
Dietz Thomas John director C/O TRANSCEPT PHARMACEUTICAL, INC. 1003 W. CUTTING BLVD, STE 110 PT. RICHMOND CA 94804
Glenn Jeffrey S director 350 CAMBRIDGE AVENUE, SUITE 350 PALO ALTO CA 94306
Sachdev Amit director C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139
Patton Stephana Eilene officer: See Remarks 1010 ATLANTIC AVENUE ALAMEDA CA 94501
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET 18TH FLOOR BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Kolchinsky Peter 10 percent owner 200 BERKELEY STREET 18TH FLOOR BOSTON MA 02116

Eiger BioPharmaceuticals Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)